GSK PLC (GS71.DE) Stock Price, Forecast & Analysis

FRA:GS71 • GB00BN7SWP63

24.93 EUR
-0.11 (-0.44%)
Last: Mar 2, 2026, 07:00 PM

GS71.DE Key Statistics, Chart & Performance

Key Statistics
Market Cap50.03B
Revenue(TTM)32.67B
Net Income(TTM)5.72B
Shares2.01B
Float1.96B
52 Week High26.14
52 Week Low14.49
Yearly Dividend0.68
Dividend Yield3.23%
EPS(TTM)1.97
PE12.65
Fwd PE11.65
Earnings (Next)04-29
IPO1972-05-22
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
GS71.DE short term performance overview.The bars show the price performance of GS71.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 20 30 40

GS71.DE long term performance overview.The bars show the price performance of GS71.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years 10 20 30 40 50

The current stock price of GS71.DE is 24.93 EUR. In the past month the price increased by 12.1%. In the past year, price increased by 35.34%.

GSK PLC / GS71 Daily stock chart

GS71.DE Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to GS71.DE. When comparing the yearly performance of all stocks, GS71.DE is one of the better performing stocks in the market, outperforming 88.95% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating
GS71.DE Full Technical Analysis Report

GS71.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to GS71.DE. There are concerns on the financial health of GS71.DE while its profitability can be described as average.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
GS71.DE Full Fundamental Analysis Report

GS71.DE Financial Highlights

Over the last trailing twelve months GS71.DE reported a non-GAAP Earnings per Share(EPS) of 1.97. The EPS increased by 7.84% compared to the year before.


Industry RankSector Rank
PM (TTM) 17.5%
ROA 9.35%
ROE 34.9%
Debt/Equity 0.9
Chartmill High Growth Momentum
EPS Q2Q%9.91%
Sales Q2Q%6.17%
EPS 1Y (TTM)7.84%
Revenue 1Y (TTM)4.11%
GS71.DE financials

GS71.DE Forecast & Estimates

32 analysts have analysed GS71.DE and the average price target is 23.32 EUR. This implies a price decrease of -6.45% is expected in the next year compared to the current price of 24.93.

For the next year, analysts expect an EPS growth of 8.81% and a revenue growth 4.15% for GS71.DE


Analysts
Analysts70
Price Target23.32 (-6.46%)
EPS Next Y8.81%
Revenue Next Year4.15%
GS71.DE Analyst EstimatesGS71.DE Analyst Ratings

GS71.DE Ownership

Ownership
Inst Owners43.55%
Ins Owners0.1%
Short Float %N/A
Short RatioN/A
GS71.DE Ownership

About GS71.DE

Company Profile

GS71 logo image GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. The company develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.

Company Info

GSK PLC

980 Great West Road

Brentford MIDDLESEX GB

Employees: 68629

GS71 Company Website

GS71 Investor Relations

Phone: 442080475000

GSK PLC / GS71.DE FAQ

Can you describe the business of GSK PLC?

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. The company develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.


What is the stock price of GSK PLC today?

The current stock price of GS71.DE is 24.93 EUR. The price decreased by -0.44% in the last trading session.


What is the dividend status of GSK PLC?

GSK PLC (GS71.DE) has a dividend yield of 3.23%. The yearly dividend amount is currently 0.68.


What is the ChartMill rating of GSK PLC stock?

GS71.DE has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.


On which exchange is GS71.DE stock listed?

GS71.DE stock is listed on the Frankfurt Stock Exchange exchange.


What is the expected growth for GS71 stock?

The Revenue of GSK PLC (GS71.DE) is expected to grow by 4.15% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


Who owns GSK PLC?

You can find the ownership structure of GSK PLC (GS71.DE) on the Ownership tab.